Hysterosalpingographic evaluation following management of ectopic pregnancy

Abstract

Objective: It is to assess the ipsilateral and contralateral tubal patency by hysterosalpingography following salpingostomy and methotrexate therapy for tubal pregnancy.

Patients and methods: The study was conducted between September 2021 and October 2023. It was conducted in the radiodiagnosis and obstetrics and gynecology departments of the Al-Hussin and Al-Azher university hospitals. Patients who had undergone salpingostomy or received methotrexate treatment were included in this research. Three months after being discharged, the individuals who were seeking for fertility were assessed again for Fallopian tube patency using hysterosalpingographs. Two groups of women participated in the study: group I (N = 50) received methotrexate treatment, while group II (N = 50) had undergone salpingostomy management.

Results: The two groups (medical and surgery) did not vary statistically significantly in preserving tubal patency. Following methotrexate therapy, the ipsilateral tubal patency was 72%, and following surgical management, it was 74%. Furthermore, following methotrexate therapy, contralateral tubal patency was 92%, and 90% following salpingostomy.

Conclusion: The results point to comparable success rates with salpingostomy and methotrexate in preserving fallopian tube patency.

Keywords: Methotrexate; ectopic pregnancy; hysterosalpingography; infertility; methotrexate; salpingostomy.